The therapeutic value of natural agents to treat miRNA targeted breast cancer in African-American and Caucasian-American women

Current Drug Targets

Volumn 13, Issue 14, 2012, Pages 1917-1925

  Rahman, K M Wahidur ^a   Sakr, Wael A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

MicroRNAs; Natural agents and breast cancer racial disparity

Indexed keywords

3 INDOLEMETHANOL; 3, 3' DIINDOLYLMETHANE; BUTYRIC ACID; CURCUMIN; EPIGALLOCATECHIN GALLATE; ESTROGEN RECEPTOR ALPHA; GENISTEIN; MICRORNA; MICRORNA 130A; MICRORNA 136; MICRORNA 146; MICRORNA 148A; MICRORNA 16; MICRORNA 17; MICRORNA 186; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 21; MICRORNA 221; MICRORNA 22B; MICRORNA 31; MICRORNA 330; MICRORNA 377; MICRORNA 429; RESVERATROL; TRANSCRIPTION FACTOR ZEB1; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER RISK; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; INCIDENCE; METASTASIS INHIBITION; MICROARRAY ANALYSIS; MORTALITY; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION;

AFRICAN AMERICANS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AGENTS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MICRORNAS; TREATMENT OUTCOME;

EID: 84879321463     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012804545461     Document Type: Review

References (153)

1. American Cancer Society. Cancer Facts & Figures for African Americans 2011-2012. Atlanta: American Cancer Society.
2. Whitman S, Ansell D, Orsi J, Francois T. The racial disparity in breast cancer mortality. J Community Health 2011; 36: 588-596.
3. Adams SA, Butler WM, Fulton J., et al. Racial disparities in breast cancer mortality in a multiethnic cohort in the Southeast. Cancer 2012; 118: 2693-2699.
4. Hirschman J, Whitman S, Ansell D. The black: white disparity in breast cancer mortality: the example of Chicago. Cancer Causes Control 2007; 18: 323-333.
5. Newman LA, Martin IK. Disparities in breast cancer. Curr Probl Cancer 2007; 31: 134-156.
6. American Cancer Society, 2009-2010 AACFaFfAA, http://www.cancer.org/acs/groups/content/@nho/documents/document/cffaa20092010pdf.pdf.
7. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama 2006; 295: 2492-2502.
8. Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 2002; 11: 601-607.
9. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 2005; 97: 439-448.
10. Menashe I, Anderson WF, Jatoi I, Rosenberg PS. Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst 2009; 101: 993-1000.
11. Shi M, Guo N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev 2009; 35: 328-334.
12. Bachour T, Bennett K. The Role of MicroRNAs in Breast Cancer. J Assoc Genet Technol 2011; 37: 21-28.
13. Alshatwi AA, Shafi G, Hasan TN, et al. Differential expression profile and genetic variants of microRNAs sequences in breast cancer patients. PLoS ONE 2012; 7: e30049.
14. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
15. Wang T, Zhang X, Obijuru L, et al. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer 2007; 46: 336-347.
16. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
17. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 2009; 28: 369-378.
18. Ruvkun G. The perfect storm of tiny RNAs. Nat Med 2008; 14: 1041-1045.
19. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12.
20. Casalini P, Iorio MV. MicroRNAs and future therapeutic applications in cancer. J BUON 2009; 14 Suppl 1: S17-S22.
21. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009; 27: 5848-5856.
22. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-7070.
23. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-714.
24. Foekens JA, Sieuwerts AM, Smid M, et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A 2008; 105: 13021-13026.
25. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-688.
26. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
27. Yancy HF, Mason JA, Peters S, et al. Metastatic progression and gene expression between breast cancer cell lines from African American and Caucasian women. J Carcinog 2007; 6: 8.
28. Ahmad A, Aboukameel A, Kong D, et al. Phosphoglucose isomerase/autocrine motility factor mediates epithelialmesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res 2011; 71: 3400-3409.
29. Korpal M, Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 2008; 5: 115-119.
30. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.
31. Wright JA, Richer JK, Goodall GJ. microRNAs and EMT in mammary cells and breast cancer. J Mammary Gland Biol Neoplasia 2010; 15: 213-223.
32. Gregory PA, Bracken CP, Bert AG, Goodall GJ. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008; 7: 3112-3118.
33. Li Y, VandenBoom TG, 2nd, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-tomesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69: 6704-6712.
34. Oba S, Kumano S, Suzuki E, et al. miR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS ONE 2010; 5: e13614.
35. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-14914.
36. Christoffersen NR, Silahtaroglu A, Orom UA, et al. miR-200b mediates post-transcriptional repression of ZFHX1B. RNA 2007; 13: 1172-1178.
37. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007; 67: 7972-7976.
38. O'Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 2010; 12: 201.
39. Cochrane DR, Howe EN, Spoelstra NS, Richer JK. Loss of miR-200c: A marker of aggressiveness and chemoresistance in female reproductive cancers. J Oncol 2010; 2010: 821717.
40. Radisky DC. miR-200c at the nexus of epithelial-mesenchymal transition, resistance to apoptosis, and the breast cancer stem cell phenotype. Breast Cancer Res 2011; 13: 110.
41. Dykxhoorn DM, Wu Y, Xie H, et al. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS ONE 2009; 4: e7181.
42. Korpal M, Ell BJ, Buffa FM, et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011; 17: 1101-1108.
43. Jurmeister S, Baumann M, Balwierz A, et al. MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol Cell Biol 2012; 32: 633-651.
44. Ichikawa T, Sato F, Terasawa K, et al. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PLoS ONE 2012; 7: e31422.
45. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 2006; 5: 2220-2222.
46. Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007; 67: 1424-1429.
47. Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 2008; 105: 13556-13561.
48. Toyota M, Suzuki H, Sasaki Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008; 68: 4123-4132.
49. Huang YW, Liu JC, Deatherage DE, et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 2009; 69: 9038-9046.
50. Huang J. Current progress in epigenetic research for hepatocarcinomagenesis. Sci China C Life Sci 2009; 52: 31-42.
51. Ceppi P, Mudduluru G, Kumarswamy R, et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 2010; 8: 1207-1216.
52. Neves R, Scheel C, Weinhold S, et al. Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Res Notes 2010; 3: 219.
53. Vrba L, Jensen TJ, Garbe JC, et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS ONE 2010; 5: e8697.
54. Wiklund ED, Bramsen JB, Hulf T, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011; 128: 1327-34.
55. Bovell-Benjamin A, Dawkins N, Pace R, Shikany JM. Dietary consumption practices and cancer risk in African Americans in the rural South. J Health Care Poor Underserved 2010; 21: 57-75.
56. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
57. Block G. Dietary guidelines and the results of food consumption surveys. Am J Clin Nutr 1991; 53: 356S-357S.
58. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 1992; 18: 1-29.
59. Verhoeven DT, Goldbohm RA, van Poppel G, et al. Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol Biomarkers Prev 1996; 5: 733-748.
60. Ahmad A, Sakr WA, Rahman KM. Novel targets for detection of cancer and their modulation by chemopreventive natural compounds. Front Biosci (Elite Ed) 2012; 4: 410-425.
61. Siu D. Natural products and their role in cancer therapy. Med Oncol 2011; 28: 888-900.
62. Banerjee S, Wang Z, Mohammad M, et al. Efficacy of selected natural products as therapeutic agents against cancer. J Nat Prod 2008; 71: 492-496.
63. Li Y, Kong D, Wang Z, Sarkar FH. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res 2010; 27: 1027-1041.
64. Banerjee S, Padhye S, Azmi A, et al. Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr Cancer 2010; 62: 938-946.
65. Li Y, Kong D, Wang Z, et al. Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells. Cancer Prev Res (Phila) 2011; 4: 1495-1506.
66. Ahmad A, Sakr WA, Rahman KM. Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. Curr Drug Targets 2010; 11: 652-666.
67. Guo S, Yang S, Taylor C, Sonenshein GE. Green tea polyphenol epigallocatechin-3 gallate (EGCG) affects gene expression of breast cancer cells transformed by the carcinogen 7,12-dimethylbenz [a]anthracene. J Nutr 2005; 135: 2978S-2986S.
68. Lopresti AL, Hood SD, Drummond PD. Multiple antidepressant potential modes of action of curcumin: a review of its antiinflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. Journal of psychopharmacology 2012.
69. Aluyen JK, Ton QN, Tran T, et al. Resveratrol: potential as anticancer agent. Journal of dietary supplements 2012; 9: 45-56.
70. Vitale DC, Piazza C, Melilli B, et al. Isoflavones: estrogenic activity, biological effect and bioavailability. European journal of drug metabolism and pharmacokinetics 2012.
71. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006; 96: 252-261.
72. Scott DW, Longpre JM, Loo G. Upregulation of GADD153 by butyrate: involvement of MAPK. DNA and cell biology 2008; 27: 607-614.
73. Semov A, Iourtchenco L, Lin Fang L, et al. Diindolilmethane (DIM) selectively inhibits cancer stem cells. Biochem Biophys Res Commun 2012; 424: 45-51.
74. Sarkar FH, Li Y. Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev 2009; 35: 597-607.
75. Ahmad A, Ali S, Wang Z, et al. 3,3'-diindolylmethane enhances taxotere-induced growth inhibition of breast cancer cells through downregulation of FoxM1. Int J Cancer 2011; 129: 1781-1791.
76. Rahman KM, Ali S, Aboukameel A, et al. Inactivation of NF-kB by 3, 3'-diindolylmethane (DIM) contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Molecular Cancer Therapeutics 2007; 6: 1-9.
77. Rahman KM, Banerjee S, Ali S, et al. 3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer Res 2009; 69: 4468-4475.
78. Ali S, Varghese L, Pereira L, et al. Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents. Cancer Lett 2009; 278: 201-209.
79. Sarkar FH, Li Y, Wang Z, et al. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 2010; 13: 57-66.
80. Siddiqui IA, Asim M, Hafeez BB, et al. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. Faseb J 2011; 25: 1198-1207.
81. Reuter S, Gupta SC, Park B, et al. Epigenetic changes induced by curcumin and other natural compounds. Genes & nutrition 2011; 6: 93-108.
82. Chen J, Xu X. Diet, epigenetic, and cancer prevention. Advances in genetics 2010; 71: 237-255.
83. Chen Y, Xu J, Jhala N, et al. Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3'-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein. Am J Pathol 2006; 169: 1833-1842.
84. Kim YH, Kwon HS, Kim DH, et al. 3,3'-diindolylmethane attenuates colonic inflammation and tumorigenesis in mice. Inflamm Bowel Dis 2009; 15: 1164-1173.
85. Chang X, Tou JC, Hong C, et al. 3,3'-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice. Carcinogenesis 2005; 26: 771-778.
86. Rahman KM, Sarkar FH. Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'-diindolylmethaneinduced apoptosis in breast cancer cells. Cancer Res 2005; 65: 364-371.
87. Rahman KW, Li Y, Wang Z, et al. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 2006; 66: 4952-4960.
88. Melkamu T, Zhang X, Tan J, et al. Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 2010; 31: 252-258.
89. Izzotti A, Calin GA, Arrigo P, et al. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. Faseb J 2009; 23: 806-812.
90. Vandenboom Ii TG, Li Y, Philip PA, Sarkar FH. MicroRNA and Cancer: Tiny Molecules with Major Implications. Curr Genomics 2008; 9: 97-109.
91. Ahmad A, Ali S, Sakr W, Rahman KM. 3, 3'-diindolylmethane enhances the effectiveness of Herceptin by upregulation of miR-200 through down-regulation of FoxM1 in breast cancer cells. (Abs 579). 2012: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research 2012.
92. Kong D, Heath E, Chen W, et al. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. Am J Transl Res 2012; 4: 14-23.
93. Kong D, Heath E, Chen W, et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS ONE 2012; 7: e33729.
94. Carroll CE, Benakanakere I, Besch-Williford C, et al. Curcumin delays development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz [a]anthracene-induced mammary tumors. Menopause 2010; 17: 178-184.
95. Banerjee S, Kong D, Wang Z, et al. Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic. Mutat Res 2011; 728: 47-66.
96. Kong D, Li Y, Wang Z, et al. miR-200 regulates PDGF-Dmediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009; 27: 1712-1721.
97. Jin Y, Zou X, Feng X. 3,3'-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA 21 in human breast cancer cells. Anticancer Drugs 2010; 21: 814-822.
98. Heath EI, Heliburn LK, Vaishampayan UN, et al. A phase I doseescalation study of oral BR-DIM (BioResponse 3,3'-Diindolyl methane) in castrate-resistant, non-metastatic, PSA relapse prostate cancer patients. GU ASCO 2009, # 188. URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=64&abstractID=20284
99. Henning SM, Wang P, Heber D. Chemopreventive effects of tea in prostate cancer: Green tea versus black tea. Mol Nutr Food Res 2011; 55: 905-920.
100. Tang SN, Singh C, Nall D, et al. The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal 2010; 5: 14.
101. Yang CS, Wang H, Li GX, et al. Cancer prevention by tea: Evidence from laboratory studies. Pharmacol Res 2011; 64: 113-122.
102. Moiseeva EP, Almeida GM, Jones GD, Manson MM. Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol Cancer Ther 2007; 6: 3071-3079.
103. Thangapazham RL, Passi N, Maheshwari RK. Green tea polyphenol and epigallocatechin gallate induce apoptosis and inhibit invasion in human breast cancer cells. Cancer Biol Ther 2007; 6: 1938-1943.
104. Spinella F, Rosano L, Di Castro V, et al. Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol Cancer Ther 2006; 5: 1483-1492.
105. Thyagarajan A, Zhu J, Sliva D. Combined effect of green tea and Ganoderma lucidum on invasive behavior of breast cancer cells. Int J Oncol 2007; 30: 963-969.
106. Tsang WP, Kwok TT. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J Nutr Biochem 2010; 21: 140-146.
107. Wang H, Bian S, Yang CS. Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1alpha. Carcinogenesis 2011; 32: 1881-1889.
108. Karius T, Schnekenburger M, Dicato M, Diederich M. MicroRNAs in cancer management and their modulation by dietary agents. Biochem Pharmacol 2012; 83: 1591-1601.
109. Chakrabarti M, Khandkar M, Banik NL, Ray SK. Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells. Brain research 2012; 1454: 1-13.
110. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9: 435-443.
111. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23: 363-398.
112. Everett PC, Meyers JA, Makkinje A, et al. Preclinical assessment of curcumin as a potential therapy for B-CLL. Am J Hematol 2007; 82: 23-30.
113. Li L, Aggarwal BB, Shishodia S, et al. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004; 101: 2351-2362.
114. Li L, Ahmed B, Mehta K, Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 2007; 6: 1276-1282.
115. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005; 104: 1322-1331.
116. Li M, Zhang Z, Hill DL, et al. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 2007; 67: 1988-1996.
117. Liang T, Chen MJ, Zhou KY, et al. [Induction of apoptosis in human nasopharyngeal carcinoma cell line CNE-2Z by curcumin]. Ai Zheng 2004; 23: 1651-1654.
118. Nakamura K, Yasunaga Y, Segawa T, et al. Curcumin downregulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol 2002; 21: 825-830.
119. Saini S, Arora S, Majid S, et al. Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev Res (Phila) 2011; 4: 1698-1709.
120. Anaund P, Sundaram C, Jhurani S, et al. Curcumin and cancer: an "old-age" disease with an "ageold"solution. Cancer Lett. 2008;267: 133-164.
121. Sarkar FH, Li Y, Wang Z, Kong D. Cellular signaling perturbation by natural products. Cell Signal 2009; 21: 1541-1547.
122. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, et al. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001; 20: 7597-7609.
123. Saini S, Majid S, Dahiya R. Diet, microRNAs and prostate cancer. Pharm Res 2010; 27: 1014-1026.
124. Fu S, Kurzrock R. Development of curcumin as an epigenetic agent. Cancer 2010; 116: 4670-4676.
125. Mudduluru G, George-William JN, Muppala S, et al. Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Biosci Rep 2011; 31: 185-197.
126. Sun M, Estrov Z, Ji Y, et al. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 2008; 7: 464-473.
127. Zhang J, Du Y, Wu C, et al. Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186* signaling pathway. Oncol Rep 2010; 24: 1217-1223.
128. Tang N, Zhang J, Du Y. [Curcumin promoted the apoptosis of cisplain-resistant human lung carcinoma cells A549/DDP through down-regulating miR-186*]. Zhongguo Fei Ai Za Zhi 2010; 13: 301-306.
129. Yang J, Cao Y, Sun J, Zhang Y. Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Med Oncol 2010; 27: 1114-1118.
130. Bao B, Ali S, Kong D, et al. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS ONE 2011; 6: e17850.
131. Lu F, Zahid M, Wang C, et al. Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells. Cancer Prev Res (Phila) 2008; 1: 135-145.
132. Wang Y, Lee KW, Chan FL, et al. The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells. Toxicol Sci. 2006; 92: 71-77.
133. Alkhalaf M. Resveratrol-Induced Apoptosis Is Associated with Activation of p53 and Inhibition of Protein Translation in T47D Human Breast Cancer Cells. Pharmacology. 2007;80: 134-143.
134. Pozo-Guisado E, Merino JM, Mulero-Navarro S, et al. Resveratrolinduced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer 2005; 115: 74-84.
135. Tili E, Michaille JJ, Alder H, et al. Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFbeta signaling pathway in SW480 cells. Biochem Pharmacol 2010; 80: 2057-2065.
136. Lancon A, Kaminski J, Tili E, et al. Control of MicroRNA Expression as a New Way for Resveratrol To Deliver Its Beneficial Effects. J Agric Food Chem 2012; 60(36): 8783-8789.
137. Tili E, Michaille JJ. Resveratrol, MicroRNAs, Inflammation, and Cancer. J Nucleic Acids 2011; 2011: 102-431.
138. Selcuklu SD, Donoghue MT, Spillane C. miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans 2009; 37: 918-925.
139. Knutson MD, Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev 2008; 66: 591-596.
140. Tili E, Michaille JJ, Adair B, et al. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis 2010; 31: 1561-1566.
141. Lukiw WJ, Zhao Y, Cui JG. An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 2008; 283: 31315-31322.
142. Chen Y, Zaman MS, Deng G, et al. MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev Res (Phila) 2011; 4: 76-86.
143. Sun Q, Cong R, Yan H, et al. Genistein inhibits growth of human uveal melanoma cells and affects microRNA-27a and target gene expression. Oncol Rep 2009; 22: 563-567.
144. Bao B, Wang Z, Ali S, et al. Notch-1 induces epithelialmesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 2011; 307: 26-36.
145. Bao B, Wang Z, Ali S, et al. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem 2011; 112: 2296-2306.
146. Majid S, Dar AA, Saini S, et al. Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer. Cancer Res 2010; 70: 2809-2818.
147. Ahn J, Albanes D, Peters U, et al. Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2007; 16: 2623-2630.
148. Ben-Shoshan M, Amir S, Dang DT, et al. 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther 2007; 6: 1433-1439.
149. Pike JW, Meyer MB, Martowicz ML, et al. Emerging regulatory paradigms for control of gene expression by 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 2010; 121: 130-135.
150. Wang WL, Chatterjee N, Chittur SV, et al. Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer 2011; 10: 58.
151. Lutherborrow M, Bryant A, Jayaswal V, et al. Expression profiling of cytogenetically normal acute myeloid leukemia identifies microRNAs that target genes involved in monocytic differentiation. Am J Hematol 2011; 86: 2-11.
152. Jorde R, Svartberg J, Joakimsen RM, Coucheron DH. Plasma profile of microRNA after supplementation with high doses of vitamin D3 for 12 months. BMC Res Notes 2012; 5: 245.
153. Hu S, Dong TS, Dalal SR, et al. The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. PLoS ONE 2011; 6: e16221.